Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension

Figures

• 

  Figure 1. Mean plasma concentration profile of sildenafil (a) and N‐desmethyl‐sildenafil (b) following administration of sildenafil alone and coadministration of sildenafil and sacubitril/valsartan.

• 

  Figure 2. Mean plasma concentration profile of sacubitril/valsartan analytes sacubitril (a), sacubitrilat (b), and valsartan (c) following administration of sildenafil alone and coadministration of sildenafil and sacubitril/valsartan.

• 

  Figure 3. Change in mean ambulatory blood pressure measurements from baseline over treatment period. (a) Change in mean aSBP, (b) mean aDBP, and (c) mean aMAP measurements during sildenafil single dose treatment, sacubitril/valsartan steady state treatment, and coadministration of sacubitril/valsartan with sildenafil. aDBP, ambulatory diastolic blood pressure; aMAP, ambulatory mean arterial pressure; aSBP, ambulatory systolic blood pressure.

• 

  Figure 4. Change in geometric mean (95% CI) of biomarkers over various treatment periods. Change in creatinine‐indexed urine cGMP (a) and urine ANP (b) over 24‐h time period during sildenafil single dose, sacubitril/valsartan steady state treatment, and coadministration of sacubitril/valsartan and sildenafil. ANP, atrial natriuretic peptide; cGMP, cyclic guanosine monophosphate; CI, confidence interval.